PD-L1 CPS < 1的hpv相关外阴和阴道鳞状细胞癌的新辅助化疗免疫治疗：双pCR证据

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2025-09-08 DOI:10.1016/j.gore.2025.101952

Enyu Tang , Jia Zeng , Yangchun Sun

{"title":"PD-L1 CPS < 1的hpv相关外阴和阴道鳞状细胞癌的新辅助化疗免疫治疗：双pCR证据","authors":"Enyu Tang , Jia Zeng , Yangchun Sun","doi":"10.1016/j.gore.2025.101952","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>While surgery and radiotherapy remain primary treatments for HPV-associated vulvar/vaginal squamous cell carcinoma (SCC), the significant complications and impaired quality of life underscore the need for alternative approaches. We report two cases achieving pathological complete response (pCR) with neoadjuvant chemoimmunotherapy.</div></div><div><h3>Cases</h3><div>Two biopsy-confirmed HPV-associated vulvar/vaginal SCC cases with inguinal lymph node metastases (both PD-L1 CPS < 1) received three cycles of neoadjuvant camrelizumab plus nab-paclitaxel/cisplatin. Subsequent imaging demonstrated marked tumor regression, permitting urethra-preserving resection. Histopathological analysis confirmed pCR, with no recurrence at 6-month follow-up.</div></div><div><h3>Conclusion</h3><div>Neoadjuvant chemoimmunotherapy may be an effective treatment for HPV-associated vulvar/vaginal SCC, potentially independent of PD-L1 CPS status, while improving post-treatment quality of life compared to conventional therapies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101952"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant chemoimmunotherapy in HPV-associated vulvar and vaginal squamous cell carcinoma with PD-L1 CPS < 1:Dual pCR evidence\",\"authors\":\"Enyu Tang , Jia Zeng , Yangchun Sun\",\"doi\":\"10.1016/j.gore.2025.101952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>While surgery and radiotherapy remain primary treatments for HPV-associated vulvar/vaginal squamous cell carcinoma (SCC), the significant complications and impaired quality of life underscore the need for alternative approaches. We report two cases achieving pathological complete response (pCR) with neoadjuvant chemoimmunotherapy.</div></div><div><h3>Cases</h3><div>Two biopsy-confirmed HPV-associated vulvar/vaginal SCC cases with inguinal lymph node metastases (both PD-L1 CPS < 1) received three cycles of neoadjuvant camrelizumab plus nab-paclitaxel/cisplatin. Subsequent imaging demonstrated marked tumor regression, permitting urethra-preserving resection. Histopathological analysis confirmed pCR, with no recurrence at 6-month follow-up.</div></div><div><h3>Conclusion</h3><div>Neoadjuvant chemoimmunotherapy may be an effective treatment for HPV-associated vulvar/vaginal SCC, potentially independent of PD-L1 CPS status, while improving post-treatment quality of life compared to conventional therapies.</div></div>\",\"PeriodicalId\":12873,\"journal\":{\"name\":\"Gynecologic Oncology Reports\",\"volume\":\"61 \",\"pages\":\"Article 101952\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologic Oncology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352578925001778\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925001778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

虽然手术和放疗仍然是hpv相关外阴/阴道鳞状细胞癌（SCC）的主要治疗方法，但明显的并发症和生活质量下降强调了替代方法的必要性。我们报告两例实现病理完全缓解（pCR）与新辅助化疗免疫治疗。两例活检证实hpv相关外阴/阴道SCC伴腹沟淋巴结转移（均为PD-L1 CPS <； 1）的病例接受了三个周期的新辅助camrelizumab加nab-紫杉醇/顺铂。随后的影像学显示肿瘤明显消退，允许保留尿道的切除。组织病理学分析证实pCR，随访6个月无复发。结论新辅助化疗免疫治疗可能是hpv相关外阴/阴道SCC的有效治疗方法，可能与PD-L1 CPS状态无关，同时与常规治疗相比，可改善治疗后的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neoadjuvant chemoimmunotherapy in HPV-associated vulvar and vaginal squamous cell carcinoma with PD-L1 CPS < 1:Dual pCR evidence

Background

While surgery and radiotherapy remain primary treatments for HPV-associated vulvar/vaginal squamous cell carcinoma (SCC), the significant complications and impaired quality of life underscore the need for alternative approaches. We report two cases achieving pathological complete response (pCR) with neoadjuvant chemoimmunotherapy.

Cases

Two biopsy-confirmed HPV-associated vulvar/vaginal SCC cases with inguinal lymph node metastases (both PD-L1 CPS < 1) received three cycles of neoadjuvant camrelizumab plus nab-paclitaxel/cisplatin. Subsequent imaging demonstrated marked tumor regression, permitting urethra-preserving resection. Histopathological analysis confirmed pCR, with no recurrence at 6-month follow-up.

Conclusion

Neoadjuvant chemoimmunotherapy may be an effective treatment for HPV-associated vulvar/vaginal SCC, potentially independent of PD-L1 CPS status, while improving post-treatment quality of life compared to conventional therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.